1
|
Konrad SM, Schwamborn K, Krüger A, Honert K, Schmitt M, Hellmann D, Schmalfeldt B, Meindl A, Kiechle M, Quante AS, Brambs C, Grill S, Ramser J. NCALD as a potential predictive biomarker for the efficacy of platinum-based chemotherapy in ovarian cancer. Biomark Med 2022; 16:1029-1041. [PMID: 36444691 DOI: 10.2217/bmm-2021-0781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Aim: Since reliable response predictors to platinum-based chemotherapy in ovarian cancer (OC) are scarce, we characterize NCALD as a predictive biomarker. Materials & methods: NCALD mRNA (n = 100) and protein (n = 102) expression was analyzed in OC samples and associated with patient outcome. A stable OC cell line knockdown was generated and cellular response to platinum was explored. Results: High NCALD mRNA and protein expression was significantly associated with longer overall patient survival (p = 0.037/0.002). Knockdown experiments revealed a significant association between cisplatin sensitivity and NCALD expression. Conclusion: Low NCALD expression was associated with reduced sensitivity to platinum-based chemotherapy. NCALD may be a new biomarker candidate to identify patients who might benefit from platinum-based chemotherapy.
Collapse
Affiliation(s)
- Sarah M Konrad
- Department of Gynecology & Obstetrics, University Hospital rechts der Isar, Technical University of Munich, Munich, 81675, Germany.,German Cancer Consortium (DKTK), partner site München, & German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany
| | - Kristina Schwamborn
- Institute of Pathology, School of Medicine, Technical University of Munich, Munich, 81675, Germany
| | - Achim Krüger
- Institute of Experimental Oncology & Therapy Research, School of Medicine, Technical University of Munich, Munich, 81675, Germany
| | - Katja Honert
- Institute of Experimental Oncology & Therapy Research, School of Medicine, Technical University of Munich, Munich, 81675, Germany
| | - Manfred Schmitt
- Department of Gynecology & Obstetrics, University Hospital rechts der Isar, Technical University of Munich, Munich, 81675, Germany
| | - Daniela Hellmann
- Department of Gynecology & Obstetrics, University Hospital rechts der Isar, Technical University of Munich, Munich, 81675, Germany
| | - Barbara Schmalfeldt
- Department of Gynecology & Obstetrics, University Hospital rechts der Isar, Technical University of Munich, Munich, 81675, Germany.,Department of Gynecology & Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, 20251, Germany
| | - Alfons Meindl
- Department of Gynecology & Obstetrics, University Hospital rechts der Isar, Technical University of Munich, Munich, 81675, Germany.,Department of Gynecology & Obstetrics, University Hospital Munich, Ludwig-Maximilians-Universität München, Munich, 81377, Germany
| | - Marion Kiechle
- Department of Gynecology & Obstetrics, University Hospital rechts der Isar, Technical University of Munich, Munich, 81675, Germany
| | - Anne S Quante
- Department of Gynecology & Obstetrics, University Hospital rechts der Isar, Technical University of Munich, Munich, 81675, Germany.,Institute of Human Genetics, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, 79106, Germany
| | - Christine Brambs
- Department of Gynecology & Obstetrics, Cantonal Hospital of Lucerne, Lucerne, 6000, Switzerland
| | - Sabine Grill
- Department of Gynecology & Obstetrics, University Hospital rechts der Isar, Technical University of Munich, Munich, 81675, Germany
| | - Juliane Ramser
- Department of Gynecology & Obstetrics, University Hospital rechts der Isar, Technical University of Munich, Munich, 81675, Germany
| |
Collapse
|